

Date: 11.08.2021

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter ended June 30, 2021.

Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board has at its meeting held on today approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021.


Please find enclosed herewith Unaudited Financial Results along with Limited Review Report for the quarter ended on June 30, 2021.

The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 02:30 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For Link Pharma Chem Limited


Bhushan Joshi
Company Secretary



Encl: As above

**Link****Pharma Chem Ltd.**

ISO-9001 - 2015

ISO-14001 - 2015

REGISTERED OFFICE :

Plot No. 161/1, 162, G.I.D.C.,

Nandesari - 391340,

Dist. Baroda (Gujarat) (India)

Tel. (O) (0265) 2840281 / 2840282

E-Mail : linkpharmalimited@gmail.com

CIN: L24230 GJ1984 PLC 007540

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	1336.98	1124.27	510.02	3,481.26
	Other income	1.42	2.15	0.02	2.15
	Total Income (A)	1338.41	1126.42	510.04	3483.41
2	Expenses:				
	Cost of materials consumed	878.26	676.89	127.57	1,793.26
	Changes in inventories of finished goods and work-in-progress	36.26	9.53	(9.89)	(15.59)
	Employee benefits expense	137.58	151.00	113.18	562.86
	Finance costs	15.18	10.74	10.34	44.04
	Depreciation and amortization expense	21.85	17.81	23.20	87.40
	Other Expenses	183.99	223.32	201.16	843.59
	Total expenses (B)	1273.12	1089.29	465.56	3315.56
3	Profit before tax (C) = (A-B)	65.29	37.13	44.48	167.85
4	Tax expense:				
	(1) Current tax	16.47	13.74	12.00	38.51
	(2) MAT credit recognised	-	10.55	-	25.55
	(3) Deferred tax	-	-3.33	-	(4.70)
	Total tax expense (D)	16.47	20.96	12.00	59.36
5	Profit for the year (E) = (C-D)	48.82	16.17	32.48	108.49
6	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss	-	3.06	-	6.06
	Income tax effect on above	-	(1.19)	-	(1.79)
	Total other comprehensive income for the year, net of tax (F)	-	1.87	-	4.27
7	Total comprehensive income for the year (Net of Tax)	48.82	18.04	32.48	112.76
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06
	Earnings per equity share (FV of Rs. 10) (Rs.)				
	Basic and Diluted	1.10	0.35	0.73	2.44

Notes:

- These unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their respective meeting held on 11.08.2021. The Limited Review of these results as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been complied by Statutory Auditors of the Company.
- The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- The financial results have been prepared in accordance with the Indian Accounting standard (Ind AS 108).
- The Company does not anticipate significant impact of COVID-19 (now referred to as second wave of the pandemic) on operations of the Company.
- Previous period/year figures have been regrouped and/ or re-arranged wherever necessary to make their classification comparable with the current period/year.



For Link Pharma Chem Limited

Satish G. Thakur
Chairman & Whole-time Director
(DIN : 00292129)

Date : 11-08-2021

Place : Vadodara




S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.
(O) : 0265-2983872, (M) : 98254 83162, E-mail : sanjaysoni@gmail.com

Independent Auditor's Reports on Quarterly Standalone Financial Results and standalone year to date Result of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

TO THE BOARD OF DIRECTORS OF
LINK PHARMA CHEM LIMITED

- 1 We have reviewed the accompanying statement of standalone Unaudited financial Results of LINK PHARMA CHEM LTD. ("the Company"), for the Quarter ended June 30, 2021 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
- 2 This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the companies Act, 2013 read with circular issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3 We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 4 Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other recognised accounting practice and policies has not disclosed the information required to be disclosed in terms of regulation, read with the circular, including the manner in which it is to be disclosed, or the it contains any material misstatement.

For SANJAY SONI & ASSOCIATES
Chartered Accountants
FRN 113251W


CA Sanjay Soni

Partner

M. No. 040616

UDIN: 21040616AAAA57578

Place: Baroda

Date: 11.08.2021

